Crossmark

Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review

Published Online: 2025-11-18

Published Print: 2026-01

Authors

DeLacey, Sean E. https://orcid.org/0000-0002-7955-5732
Dieguez, Abigayil C.

Bensignor, Megan O.
License Information

Text and Data Mining valid from 2025-11-18

Version of Record valid from 2025-11-18
More Information

Article History

Received: 7 October 2025

Accepted: 31 October 2025

First Online: 18 November 2025

Declarations

:

: Abigayil Dieguez declares that she has no competing interests. Megan O. Bensignor receives research support as a discounted study drug from Vivus Inc and discontinued monitors from Dexcom. Sean DeLacey receives research support for medical devices from Dexcom.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current